Safe and Timely Antithrombotic Removal (STAR) Registry
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: CytoSorb.
- Who it may be relevant to
- Registry conditions: Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Austria, Belgium, Germany, Sweden, Switzerland +1
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Safe and Timely Antithrombotic Removal (STAR) Registry: International Registry on the Use of CytoSorb for Removal of Antithrombotic Agents in the Acute Hospital Setting
Overview
This registry will capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb for the removal of antithrombotic agents.
Detailed description
The STAR Registry will collect patient-level clinical data on antithrombotic removal with CytoSorb. The decision to use CytoSorb in this clinical setting is based on the clinical rationale of mitigating the high risk of bleeding events that is directly linked to the presence of the antithrombotic agent. This registry is to capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb. Data of retrospective and prospective patients will be included in the registry. Safety will be assessed by collection of (at least possibly) device-related adverse events. Data collection is done up to 30 days post-operation.
Interventions
- Device CytoSorb
Sorbent hemoperfusion system
Primary outcome measures
- Bleeding complications including requirements for transfusions and other blood products [Time frame: Assessed until postoperative day (POD) 3, date of ICU discharge, or date of death, whatever comes first; on average 3 days]
Eligibility criteria
Inclusion criteria
- CytoSorb utilization for antithrombotic removal
- Informed consent for prospective registry participation
Exclusion criteria
- Use of CytoSorb for purpose other than antithrombotic removal
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Germany · 15 centers
- Evangelisches Herzzentrum Coswig — Coswig
- Herzchirurgische Klinik Erlangen — Erlangen
- Universitätsklinikum Essen — Essen
- Asklepios Kliniken Hamburg GmbH — Hamburg
- Medizinische Hochschule Hannover — Hanover
- Universitätsklinikum Heidelberg - Klinik für Herzchirurgie — Heidelberg
- Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Herz- und Gefäßchirurgie — Kiel
- Herzzentrum Leipzig and Helios Health Institute GmbH Leipzig — Leipzig
- … and 7 more centers
Austria · 4 centers
- Universitätsklinikum Graz — Graz
- Medizinische Universität Innsbruck — Innsbruck
- Klinikum Klagenfurt am Wörthersee — Klagenfurt
- Medical University of Vienna — Vienna
Belgium · 4 centers
- Centre Hospitalier Universitaire de Liège — Liège
- OLV ziekenhuis Aalst VZW — Aalst
- Cliniques Universitaires Saint-Luc — Brussels
- University Hospital Ghent — Ghent
Switzerland · 3 centers
- Hôpitaux Universitaires Genève — Geneva
- Stadtspital Zürich Clinic for Cardiac Surgery — Zurich
- Universitätsspital Zürich — Zurich
United Kingdom · 3 centers
- Blackpool Teaching Hospitals NHS Foundation Trust/ Blackpool Victoria Hospital — Blackpool
- Royal Brompton & Harefield Clinical Group (part of Guy's and St Thomas' NHS Foundation TRU — London
- Sheffield Teaching Hospitals NHS Foundation Trust — Sheffield
Sweden · 1 center
- Skåne University Hospital Lund — Lund
Publications
- Schmoeckel M, Thielmann M, Hassan K, Geidel S, Schmitto J, Meyer AL, Vitanova K, Liebold A, Marczin N, Bernardi MH, Tandler R, Lindstedt S, Matejic-Spasic M, Wendt D, Deliargyris EN, Storey RF. Intraoperative haemoadsorption for antithrombotic drug removal during cardiac surgery: initial report of the international safe and timely antithrombotic removal (STAR) registry. J Thromb Thrombolysis. 2024 PMID 38709456
- Schmitto J, De Somer F, Thielmann M, Marczin N, Ruhparwar A, Meyer AL, Hagl C, Matejic-Spasic M, Wendt D, Fan W, Deliargyris EN, Storey RF, Schmoeckel M. Intraoperative antithrombotic drug removal during heart transplantation: A case series from the International Safe and Timely Antithrombotic Removal (STAR) registry. JHLT Open. 2025 Aug 20;10:100369. doi: 10.1016/j.jhlto.2025.100369. eCollection PMID 40933270
- Storey RF, Hassan K, Meyer AL, Eberle T, deNeve N, Thielmann M, Bernardi MH, Marczin N, Guenther U, Panholzer B, Maechler H, Hunter S, Matejic-Spasic M, Wendt D, Deliargyris EN, Schmoeckel M. Early CABG with intraoperative hemoadsorption in patients on ticagrelor: Real-world data from the international Safe and Timely Antithrombotic Removal (STAR) registry. Cardiovasc Revasc Med. 2026 Jan;82:50-56 PMID 40044567
- Schmoeckel M, Thielmann M, Vitanova K, Eberle T, Marczin N, Hassan K, Liebold A, Lindstedt S, Machler G, Matejic-Spasic M, Wendt D, Deliargyris EN, Storey RF. Direct-acting oral anticoagulant removal by intraoperative hemoadsorption in CABG and/or single valve surgery: interim analysis of the International Safe and Timely Antithrombotic Removal (STAR) registry. J Cardiothorac Surg. 2025 Jan 20;20( PMID 39833891
Identifiers
NCT: NCT05077124 · O05